Everolimus

Description

Everolimus is an immunosuppressant medicine used along with other medicines to prevent the body from rejecting a kidney or a liver transplant. It may also be used to treat certain types of cancers of the breasts, kidneys, pancreas, intestines, lungs, brain, etc.

Side effects

Major & minor side effects for Everolimus

  • Swelling of the face, arms, hands, lower legs, or feet
  • Chest pain
  • Chills and fever
  • Diarrhea
  • Difficulty in swallowing
  • Difficult or painful urination
  • Rapid weight gain
  • Tingling of hands or feet
  • Bleeding gums
  • Blurred vision
  • Nausea and vomiting
  • Slow heart rate
  • Sweating
  • Unusual tiredness or weakness
  • Dry skin
  • Headache
  • Hair loss
  • Missed or irregular menstrual periods
  • Cough
  • Irregular breathing

Uses of Everolimus

What is it prescribed for?

  • Organ Transplant - Rejection Prophylaxis
  • Advanced Breast Cancer
  • Advanced Renal Cell Carcinoma (RCC)
  • Pancreatic Cancer
  • Renal Angiomyolipoma
  • Advanced Neuroendocrine Carcinoma
  • Brain/Intracranial Tumor
  • Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its effect is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. Discuss all the risks and benefits with your doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition. Alternatively, Your doctor may prescribe a safer alternative.

Allergy

This medicine is not recommended for use in patients with a known allergy to Everolimus, other rapamycin derivatives, or any other inactive ingredients present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. Discuss all the risks and benefits with your doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition. Alternatively, Your doctor may prescribe a safer alternative.
General warnings

Vaccination

The administration of live vaccines is not recommended during treatment with this medicine due to the increased risk of serious infections. Patients are advised to avoid contact with individuals who have received live vaccines. Patients are also recommended to be up to date with all required immunizations before initiating therapy with this medicine.

Blood glucose levels

This medicine may increase the serum blood glucose levels in some patients. Monitoring of fasting serum glucose levels is recommended before starting therapy with this medicine and periodically thereafter. It is recommended that blood glucose levels should be within control before initiating therapy with this medicine.

Cholesterol levels

This medicine may increase the cholesterol and triglyceride levels in some patients. Monitoring of fasting lipid profile is recommended before starting therapy with this medicine and periodically thereafter. It is recommended that lipid levels should be within control before initiating therapy with this medicine.

Wound healing and fluid accumulation

This medicine may delay wound healing and increase the risk of wound-related complications which may require surgical intervention. It also may cause fluid accumulation, including peripheral edema and other types of localized fluid collections which may lead to further complications.

Infections

The immunosuppressant effect of this medicine may decrease the resistance to infectious agents and may increase the risk of infections. Patients are advised to report any unusual symptoms such as a sore throat, pain or burning during urination, fever, chills, etc. to the doctor immediately. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Non-infectious pneumonitis

This medicine may cause non-infectious pneumonitis in some patients. Appropriate dose adjustments should be made based on the severity of the symptoms. Appropriate corrective measures or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

Angioedema

The use of this medicine, either alone or in combination with other medicines, may cause angioedema in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Proteinuria

This medicine may increase the presence of abnormal quantities of protein in the urine (proteinuria) when it is used along with cyclosporine in transplant patients. Monitoring of protein levels in urine is recommended when these medicines are used together. Appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

Infertility

Prolonged therapy with this medicine may cause male as well as female infertility. Patients with reproductive potential should discuss this risk with their physician before beginning treatment with this medicine.

Stomatitis/Mouth Sores

This medicine may cause mouth sores in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Hematologic abnormalities

This medicine should be used with caution in patients predisposed to hematologic changes due to the increased risk of severe hematologic abnormalities. These abnormalities may include decreased levels of hemoglobin, platelets, lymphocytes, white blood cells, etc. Periodic monitoring of complete blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact a doctor immediately in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Aliskiren

Angiotensin converting enzyme inhibitors (ACEI's)

Darunavir

Adalimumab

Ketoconazole

Disease interactions

Liver Disease

This medicine should be used with caution in patients with liver diseases due to the increased risk of severe adverse effects. Close monitoring of liver function tests, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Renal Disease

This medicine should be used with caution in patients with renal diseases due to the increased risk of worsening of the patient's condition. Close monitoring of renal function is recommended for such patients. Appropriate corrective measures or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Food interactions
Consumption of grapefruit or grapefruit juice is not recommended during treatment with this medicine due to the increased risk of serious adverse effects.
Lab interactions
Information not available.
Take this medicine exactly as advised by your doctor. Do not take in larger amounts than advised or share this medicine with others. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by suppressing the immune system which is primarily responsible for organ rejection after a transplant has been completed. It also stops the cancer cells from multiplying and decreases the blood supply to the cancer cells.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Selective immunosuppressants , Mtor inhibitors

Schedule

Schedule H

[Internet]. Accessdata.fda.gov. 2018 [cited 31 May 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021560s000lbl.pdf

[Internet]. Accessdata.fda.gov. 2018 [cited 31 May 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s6lbl.pdf

Everolimus: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2018 [cited 31 May 2018]. Available from:

https://medlineplus.gov/druginfo/meds/a609032.html

[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 31 May 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04

Everolimus - DrugBank [Internet]. Drugbank.ca. 2018 [cited 31 May 2018]. Available from:

https://www.drugbank.ca/drugs/DB01590

Afinitor 10mg tablets - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2018 [cited 31 May 2018]. Available from:

https://www.medicines.org.uk/emc/product/6658/smpc

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 4 Jun 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.